You searched for "carcinomas"
EAU Pocket Guidelines App
The European Association of Urology (EAU) has consistently led on the latest guidelines and advanced the care of urology since its inception. The EAU Pocket Guidelines app provides pocket guideline summaries of the full EAU Guidelines collection. The app is...Use of MRI in the evaluation of prostate cancer: part 2
Diffusion weighted imaging and contrast enhanced imaging Introduction Magnetic resonance imaging (MRI) is widely used in localisation, staging and post-treatment follow-up of prostate cancer. In the previous issue, we discussed the usefulness of MRI in depicting prostate anatomy and pairing...Urethral pathology
Case 1 A 43-year-old lady presents with urinary incontinence and vaginal pain associated with intercourse. An initial CT scan is performed. Case courtesy of Radswiki, Radiopaedia.org, rID: 12056. Case courtesy of Radswiki, Radiopaedia.org, rID: 12056 What is the clinical diagnosis...Demanding cases or nightmares in uro-oncology? May/Jun 2021
It’s not in the bag until it’s out of the abdomen: abdominal wall recurrence after ruptured retrieval bag during robot-assisted partial nephrectomy We present a case of failure of a specimen retrieval bag during a robot-assisted partial nephrectomy resulting in...Richard Wolf Range Update
Richard Wolf a global business with headquarters in Germany and over a century of tradition and expertise in the field of endoscopy. We develop, manufacture and market specific system solutions for minimally invasive human medicine.
Is AS in SRM more convincing than in prostate cancer?
This article reviews active surveillance (AS) in the management of small renal masses (SRM), the role of renal tumour biopsy (RTB), patient selection, tumour growth kinetics, and outcomes. SRMs which are defined as masses ≤4 cm in diameter and enhance...
Risk factors for CKD following treatment for RCC
This paper concerns the prevention of chronic kidney disease (CKD) following treatment for renal cell carcinoma (RCC). Over the last 10 years, partial nephrectomy has played an increasing role in the management of RCC, especially T1a disease. It has been...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...
Treatment options for renal cell carcinoma
In this issue of European Urology, experts review advancements and challenges in treating renal cell carcinoma (RCC), emphasising the complexity of managing a disease with an expanding array of therapeutic options. Despite significant progress, critical questions remain about treatment sequencing,...Recent developments in bladder cancer
There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...Assessment of the incidental adrenal lesion
Introduction The adrenal glands are seen on CT or MRI surrounded by fat in the peri-renal space. The right adrenal gland lies medial to the right lobe of the liver, lateral to the right crus of the diaphragm and superior...
